Transition Therapeutics, Novo Nordisk deal

NVO exercised its exclusive option to license TTH's Islet Neogenesis Therapy (I.N.T.) to regenerate insulin-producing cells. TTH received an option exercise fee of $200,000, and NVO will invest C$5 m...